Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Regenerative Medicines Provisions Of Cures Act A Top Priority For CBER

Jun 09 2017

• By Michael Cipriano

FDA entrance sign 2016

Related Content

Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar

Apr 24 2017

Expanded Access Amendment Could Blunt 'Right To Try' Legislation In US

May 12 2017

US FDA First's RMAT Designation: Humacyte Got A 'Quick Response'

Mar 26 2017

Will US FDA User Fee Reauthorization Bring More RATS?

Mar 05 2017

Current FDA Policy Uncertainties Could Yield 'Reverse Impact' Of Support

May 05 2017

Gottlieb Q&A: Off-Label Communications And Right-To-Try

May 03 2017

'Right To Try' And PDUFA VI: Patient Advocates, Industry Fight Senate Add-On

May 03 2017

Related Companies

Humacyte, Inc.

Enzyvant Therapeutics, Inc.

Additional Topics

United States Regenerative Medicine Legislation Regulation BioPharmaceutical

More from Cell & Gene Therapies

More from Advanced Technologies

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window